Shuttle Pharmaceuticals Enters Material Agreement
Ticker: SHPH · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $600,000, $1.3 million, $237,500, $570,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
Shuttle Pharma signed a big deal, filed equity sales & financials. Details TBD.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. announced on October 14, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and sales were not provided in this initial filing.
Why It Matters
This filing indicates a significant business development for Shuttle Pharmaceuticals, potentially impacting its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks if not managed properly.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- October 14, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, MD (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Shuttle Pharmaceuticals?
The filing states that Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on October 14, 2024, but does not provide specific details about the agreement itself.
What type of equity securities were sold unregistered?
The filing reports on unregistered sales of equity securities but does not specify the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 14, 2024.
Where are Shuttle Pharmaceuticals' principal executive offices located?
Shuttle Pharmaceuticals' principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is the standard industrial classification for Shuttle Pharmaceuticals?
The standard industrial classification for Shuttle Pharmaceuticals is Pharmaceutical Preparations [2834].
Filing Stats: 1,083 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2024-10-17 17:17:59
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $600,000 — corporation (the "Company"), closed on $600,000 of an up to $1.3 million 5% original is
- $1.3 million — mpany"), closed on $600,000 of an up to $1.3 million 5% original issue discount senior secur
- $237,500 — e Officer, Anatoly Dritschilo, invested $237,500 in the Offering. Under the terms of t
- $570,000 — the Company has received investments of $570,000, and issued a total of $600,000 in Note
- $1.53 — shares of common stock, exercisable at $1.53 per share. The Notes mature one year
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 339KB
- ex10-2.htm (EX-10.2) — 80KB
- ex10-3.htm (EX-10.3) — 116KB
- ex10-1_001.jpg (GRAPHIC) — 45KB
- ex10-2_001.jpg (GRAPHIC) — 84KB
- 0001493152-24-041443.txt ( ) — 1018KB
- shph-20241014.xsd (EX-101.SCH) — 3KB
- shph-20241014_lab.xml (EX-101.LAB) — 33KB
- shph-20241014_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: October 17, 2024 By: /s/ Timothy Lorber Name: Timothy Lorber Title: Chief Financial Officer